Literature DB >> 17617400

Stereoselective action of (+)-morphine over (-)-morphine in attenuating the (-)-morphine-produced antinociception via the naloxone-sensitive sigma receptor in the mouse.

Hsiang-en Wu1, Jau-Shyong Hong, Leon F Tseng.   

Abstract

We have previously demonstrated that (+)-morphine and (-)-morphine given spinally stereoselectively attenuate the spinally-administered (-)-morphine-produced tail-flick inhibition in the mouse. The phenomenon has been defined as antianalgesia. Present studies were then undertaken to determine if the systemic administration of (+)-morphine and (-)-morphine also stereoselectively attenuates the systemic (-)-morphine-produced tail-flick inhibition and the effects of (+)-morphine and (-)-morphine are mediated by the naloxone-sensitive sigma receptor activation in male CD-1 mice. Pretreatment with (+)-morphine at a dose of 0.01-10 ng/kg given subcutaneously dose-dependently attenuated the tail-flick inhibition produced by subcutaneously-administered (-)-morphine (5 mg/kg). Pretreatment with (-)-morphine (0.01-1.0 mg/kg) given subcutaneously also attenuates the (-)-morphine-produced tail-flick inhibition. The ED50 values for (+)-morphine and (-)-morphine for inhibiting the (-)-morphine-produced tail-flick inhibition were estimated to be 30.6 pg/kg and 97.5 microg/kg, respectively. The attenuation of the (-)-morphine-produced tail-flick inhibition induced by (+)-morphine or (-)-morphine pretreatment was reversed by the pretreatment with (+)-naloxone or by the sigma receptor antagonist BD1047 (N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide) given subcutaneously. Pretreatment with (+)-pentazocine, a selective sigma receptor agonist, (1-10 mg/kg) given subcutaneously also attenuates (-)-morphine-produced tail-flick inhibition, which was restored by (+)-naloxone (4 mg/kg) or BD1047 (10 mg/kg) pretreated subcutaneously. It is concluded that (+)-morphine exhibits extremely high stereoselective action over (-)-morphine given systemically in attenuating the systemic (-)-morphine-produced antinociception and the antianalgesic effect of (+)-morphine and (-)-morphine is mediated by activation of the naloxone-sensitive sigma receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617400      PMCID: PMC2080825          DOI: 10.1016/j.ejphar.2007.06.012

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone.

Authors:  I Iijima; J Minamikawa; A E Jacobson; A Brossi; K C Rice
Journal:  J Med Chem       Date:  1978-04       Impact factor: 7.446

2.  Sigma antagonists potentiate opioid analgesia in rats.

Authors:  C C Chien; G W Pasternak
Journal:  Neurosci Lett       Date:  1995-05-05       Impact factor: 3.046

3.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

4.  Naloxone-sensitive, haloperidol-sensitive, [3H](+)SKF-10047-binding protein partially purified from rat liver and rat brain membranes: an opioid/sigma receptor?

Authors:  L I Tsao; T P Su
Journal:  Synapse       Date:  1997-02       Impact factor: 2.562

5.  Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors?

Authors:  Y F Jacquet; W A Klee; K C Rice; I Iijima; J Minamikawa
Journal:  Science       Date:  1977-11-25       Impact factor: 47.728

6.  Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.

Authors:  S W Tam; L Cook
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  Selective antagonism of opioid analgesia by a sigma system.

Authors:  C C Chien; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

8.  Nonopioidergic mechanism mediating morphine-induced antianalgesia in the mouse spinal cord.

Authors:  Hsiang-En Wu; Jonathan Thompson; Han-Sen Sun; Randy J Leitermann; James M Fujimoto; Leon F Tseng
Journal:  J Pharmacol Exp Ther       Date:  2004-03-03       Impact factor: 4.030

9.  Naloxone-inaccessible sigma receptor in rat central nervous system.

Authors:  S W Tam
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

10.  Functional antagonism of morphine analgesia by (+)-pentazocine: evidence for an anti-opioid sigma 1 system.

Authors:  C C Chien; G W Pasternak
Journal:  Eur J Pharmacol       Date:  1993-11-30       Impact factor: 4.432

View more
  11 in total

Review 1.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.

Authors:  Linda R Watkins; Mark R Hutchinson; Kenner C Rice; Steven F Maier
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

2.  (+)-Morphine attenuates the (-)-morphine-produced tail-flick inhibition via the sigma-1 receptor in the mouse spinal cord.

Authors:  Leon F Tseng; Quinn H Hogan; Hsiang-En Wu
Journal:  Life Sci       Date:  2011-10-02       Impact factor: 5.037

3.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

4.  Preliminary pharmacological evaluation of enantiomeric morphinans.

Authors:  Anna W Sromek; Brian A Provencher; Shayla Russell; Elena Chartoff; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  ACS Chem Neurosci       Date:  2014-01-08       Impact factor: 4.418

5.  (+)-Morphine attenuates the (-)-morphine-produced conditioned place preference and the mu-opioid receptor-mediated dopamine increase in the posterior nucleus accumbens of the rat.

Authors:  Maia Terashvili; Hsiang-En Wu; Emma T Schwasinger; Kuei-Chun Hung; Jau-Shyong Hong; Leon F Tseng
Journal:  Eur J Pharmacol       Date:  2008-03-29       Impact factor: 4.432

6.  Evidence that opioids may have toll-like receptor 4 and MD-2 effects.

Authors:  Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2009-08-11       Impact factor: 7.217

7.  The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system.

Authors:  Masahiro Ohsawa; Anna Carlsson; Megumi Asato; Takayuki Koizumi; Yuki Nakanishi; Rebecca Fransson; Anja Sandström; Mathias Hallberg; Fred Nyberg; Junzo Kamei
Journal:  Mol Pain       Date:  2011-10-31       Impact factor: 3.395

8.  Sigma-1 receptor expression in sensory neurons and the effect of painful peripheral nerve injury.

Authors:  Madhavi L Bangaru; Dorothee Weihrauch; Qing-Bo Tang; Vasiliki Zoga; Quinn Hogan; Hsiang-en Wu
Journal:  Mol Pain       Date:  2013-09-10       Impact factor: 3.395

9.  Zinc involvement in opioid addiction and analgesia--should zinc supplementation be recommended for opioid-treated persons?

Authors:  Diana Ciubotariu; Cristina Mihaela Ghiciuc; Cătălina Elena Lupușoru
Journal:  Subst Abuse Treat Prev Policy       Date:  2015-08-04

10.  Toll-like receptor 4 mutant and null mice retain morphine-induced tolerance, hyperalgesia, and physical dependence.

Authors:  Theresa Alexandra Mattioli; Heather Leduc-Pessah; Graham Skelhorne-Gross; Chris J B Nicol; Brian Milne; Tuan Trang; Catherine M Cahill
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.